Aggregate Spend

AGGREGATE SPEND ARTICLES

  • Advancements In Gene Therapy Development

    Gene therapy is transforming treatment for genetic disorders. With over 30 FDA-approved therapies, gain expert insight into how digital PCR enhances AAV vector precision, safety, and regulatory compliance in development.

AGGREGATE SPEND SOFTWARE WHITE PAPERS AND CASE STUDIES

AGGREGATE SPEND PRODUCTS

With the effectiveness of 3D cell culture in many areas of research, including anti-cancer drug screening and in vitro tumor studies, the need for better methods to produce replicate spheroids of uniform size in mass quantities has emerged. The Corning Elplasia 12K flask addresses this need by enabling researchers to generate a high density of spheroids in a scaffold-free model.

The Corning Elplasia 12K flask contains 152 microcavities per cm2 in a vessel footprint similar to that of a T-75 flask. Gravity, in conjunction with the Corning Ultra-Low Attachment (ULA) surface, and a rounded microcavity geometry enable formation of approximately 12,000 spheroids of similar shape and size.

New 15 cu ft AIM Blending ribbon blender, model RB-15, 304 sanitary stainless steel construction with USDA grade #4 internal finish, 18 cu ft total capacity, 15 cu ft working capacity, approximately 25" wide x 48" long x 28" deep trough, double ribbon agitator, full hinged top cover, outboard roller bearings, sanitary split packing gland shaft seals, 6" center bottom outlet with manually operated slide gate discharge valve, 5 hp, 240/480 volt motor drive producing approximately 60 rpm shaft speed, on 304 stainless steel stand with approximately 17" discharge height, blender has been pre-wired for 240 volt, 3 phase, 60 hertz, including start/stop and E stop, serial# 015-411-SS-FG-RB-6S-2303-5VE, built 2023, New and Unused.

Ensure safe and effective development of highly potent therapies with our proven expertise, specialized facilities, and robust containment systems designed to support every drug development stage.

Natoli’s line of affordable tablet presses is designed, engineered, and manufactured in the U.S.A. and built on our decades of experience in the tableting industry. We know our customers want presses that efficiently meet their R&D and/or production needs.

With Natoli you have a choice in your tablet press: R&D or production, single-station or rotary, fully automated or manual. Whatever your need, Natoli’s best-in-class tablet presses can help you optimize tablet quality while saving time and reducing costs.

From regulatory pathway selection to patient recruitment challenges to navigating the volume of data to collect and clean — a rare disease therapy requires an extraordinary amount of coordination.

PHCbi brand’s 5.7 cu.ft (161 L) Cell-IQ stackable multigas CO₂/O₂ incubator is designed to support a contamination-free environment using passive controls like the inCu-saFe® copper-enriched stainless steel interior and optional SafeCell™ UV. The solid zirconia O₂ sensor and dual IR CO₂ sensors helps ensure rapid and precise gas recovery after door openings.

Used Nova Biomedical cell culture analyzer, model pHOx, serial# T07607151.

Apollo™ is an innovative platform that empowers you with real-time access to study data, milestones, documents, and program planning tools.

AGGREGATE SPEND SOFTWARE NEWS

ABOUT

Aggregate Spend

Aggregate Spend refers to the process used to aggregate and monitor the total amount spent on organizations and individual healthcare professionals by healthcare manufacturers. The amount spent is aggregated in terms of payments made, honoraria, gifts, travel and other means. Aggregate spend is also known as the Physician Spend Sunshine Law which is an initiative that is aimed to achieve transparency in life sciences industry, the benefits of each physician as well as to limit spend per physician. The law is a body of state and federal legislations. Passing of this law was also in effort to alleviate the conflicts of interest between pharmaceutical and medical device companies and healthcare professionals.

The process requires that manufactures of various medical devices, drugs, biological and other supplies recorded all payments made to physicians including any other transfers of value to teaching hospitals and physicians. Report regarding all this information is required to be produced annually by all the applicable manufacturers and suppliers. The manufacturers are required to include details such as date, nature of payment and the value. Penalties are charged in case of breaching this law by the target parties.

By doing this, accountability of individual physicians and medical device, pharmaceutical and life sciences companies can be achieved. The challenge now is to the life science companies to address the reporting requirements and more so now that state and federal regulatory agency continue to enact legislation that require more auditing of monetary transactions to physicians and organizations involved in healthcare management. As a result many companies are now working more diligently to address compliance and gain more competitive advantage through reputation management among other ways.